Glepaglutide: The Long-Acting GLP-2 Peptide Trying to Free Short Bowel Patients From IV Nutrition (June 30, 2026)
Table of Contents
A peptide for the gut, not the waistline
Almost every peptide making headlines right now works on metabolism: GLP-1 and GIP drugs like semaglutide and tirzepatide for weight and blood sugar. Glepaglutide is a relative — but a different one. It is an analog of glucagon-like peptide-2 (GLP-2), a hormone the intestine releases after a meal to help the gut lining grow and absorb nutrients. Developed by Zealand Pharma, glepaglutide is being tested not for obesity but for short bowel syndrome with intestinal failure (SBS-IF), a rare and serious condition where people who have lost much of their small intestine — often to Crohn's disease, surgery, injury or a vascular event — simply cannot absorb enough food and water to survive on their own.
What short bowel syndrome actually means day to day
People with severe SBS-IF depend on parenteral support: nutrition and fluids delivered intravenously, frequently for 10 to 14 hours a night, several days a week, through a permanent central line. It keeps them alive, but it is grueling. The line can get infected, the liver can suffer over years, sleep and travel and normal life are constrained, and the routine is relentless. The central goal of any SBS therapy is simple to state and hard to achieve: get the remaining gut to do more of the absorbing, so patients can reduce — or ideally stop — their IV nutrition.
How glepaglutide works: growing the gut you have left
GLP-2 is the body's own signal to build and maintain the intestinal lining. Glepaglutide is a GLP-2 receptor agonist: it switches on those receptors in the bowel, prompting the mucosa to grow taller villi and a deeper absorptive surface, increasing blood flow to the intestine, slowing how fast the stomach empties, and reducing fluid losses. The net effect is that the shortened intestine absorbs more of what passes through it, so less has to be replaced by IV. What sets glepaglutide apart from the first approved GLP-2 drug, teduglutide (Gattex/Revestive), is its engineering: it is built to stay stable in a ready-to-use liquid and has a long effective half-life of about 88 hours. That means once- or twice-weekly injections from an autoinjector instead of a daily shot — a meaningful difference for people already managing a heavy treatment load.
The evidence: what the Phase 3 trial showed
In the pivotal Phase 3 EASE-SBS 1 trial, 106 adults with SBS who relied on parenteral support were randomized to glepaglutide 10 mg once weekly, twice weekly, or placebo for 24 weeks. The twice-weekly dose hit the primary endpoint: it cut weekly IV support volume significantly more than placebo (mean change of about −5.13 versus −2.85 liters per week; P=0.0039). Roughly two-thirds of twice-weekly patients achieved a clinically meaningful response (more than a 20% reduction in IV support), and nine glepaglutide-treated patients were weaned off parenteral support entirely — compared with none on placebo. The once-weekly dose produced a numerical improvement that did not reach statistical significance, which is part of why dosing details have mattered so much to regulators.
Where it stands in 2026: a U.S. setback and a European filing
The regulatory road has been bumpy. On December 19, 2024, the U.S. FDA issued a Complete Response Letter, concluding the application did not provide enough substantial evidence of efficacy and safety for the proposed marketed dose and asking for an additional clinical trial. Zealand Pharma said it would run a new Phase 3 to pursue U.S. approval. In parallel, in June 2025 the company submitted a Marketing Authorization Application to the European Medicines Agency, supported by EASE-SBS 1 plus interim data from the EASE-2 and EASE-3 long-term extension studies. So as of mid-2026, glepaglutide is not approved anywhere yet: under review in Europe, and needing more data in the U.S. It sits in a small but real class — alongside daily teduglutide and the once-weekly candidate apraglutide (Ironwood), which the FDA has likewise asked to confirm in another trial.
Why it matters — and what to keep honest
Glepaglutide is a useful reminder that 'peptide research' stretches far past weight loss. GLP-2 analogs are intestinotrophic — they make gut tissue grow — which is exactly the point in SBS but also the reason they carry careful monitoring: surveillance for intestinal polyps, plus attention to the gallbladder, pancreas and fluid balance that come with the class. Two honest caveats belong on any 2026 write-up. First, this is an investigational, prescription-only drug for a specific rare disease under specialist care — not a wellness compound and not something sold legitimately by 'research peptide' vendors. Second, the FDA has not approved it and has asked for more evidence, so its U.S. future depends on a confirmatory trial. The promise is real: a weekly injection that could free some patients from nightly IV nutrition. The proof still has to finish coming in.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Glepaglutide, a Long-Acting GLP-2 Analogue, Reduces Parenteral Support in Short Bowel Syndrome: Phase 3 RCT (EASE-SBS 1) — Gastroenterology Source
- [2] U.S. FDA issues Complete Response Letter for the glepaglutide NDA — Zealand Pharma (Dec 19, 2024) Source
- [3] Zealand Pharma submits Marketing Authorization Application to the EMA for glepaglutide (June 2025) Source
- [4] FDA Issues Complete Response Letter for Much-Anticipated GLP-2 Analog — Pharmacy Times Source
Related Articles
Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)
Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.
Setmelanotide (Imcivree): The MC4R Peptide That Treats Obesity the GLP-1 Drugs Can't (June 26, 2026)
Setmelanotide (Imcivree) is a cyclic octapeptide that activates the brain's MC4R appetite switch directly — treating rare genetic and post-tumor hypothalamic obesity that GLP-1 drugs were never designed for. In March 2026 the FDA expanded it to acquired hypothalamic obesity, making it the first and only approved therapy for that condition.
Zosurabalpin (RG6006): The First-in-Class Macrocyclic Peptide Antibiotic Taking on a Critical Superbug (June 27, 2026)
Zosurabalpin (RG6006) is the first antibiotic of a brand-new structural class in decades — a tethered macrocyclic peptide that kills carbapenem-resistant Acinetobacter baumannii by jamming the bacterium's LPS transporter. Here's how it works and why its move into Phase 3 matters.